|
PSGN |
SAGN |
IE-GN |
Shunt Nephritis |
Epidemiology |
Mainly affects children between ages 4 and 15 |
Mainly affects adults between ages 50 and 80 |
Affects adults and those at risk (eg, IVDU, diabetes, prosthetic heart valves) |
Affects any patient with previous shunt surgery, typically within the first 5 yr postsurgery |
Infection Process |
Abrupt onset of nephritis following resolution of a streptococcal infection |
Usually no latent-free period; occurs concurrently with Staphylococcus infectious such as pneumonia |
Should be suspected in patients with IE with AKI, crescentic GN, and/or abnormal urinalysis |
Occurs in the setting of infected VA or VP shunt for hydrocephalus; indolent course and often missed |
Bacterial Strain |
Nephritogenic strains of group A Streptococcus |
MRSA, MSSA, MRSE |
Streptococcus sp. and Staphylococcus aureus |
S. epidermidis or Propionibacterium acnes |
Histopathology |
LM: diffuse proliferative and exudative GN
IF: granular deposits of C3 and IgG/IgM in capillary wall; distinct staining
EM: “hump-shaped” subepithelial deposits
|
LM: diffuse proliferative and exudative GN
IF: glomerular IgA and C3 (codominant) staining
EM: mesangial and subepithelial deposits (as in PSGN)
|
LM: diffuse crescentic pattern with focal or diffuse proliferative GN
IF: C3-dominant glomerular staining, ± IgA, IgG, or IgM
EM: electron-dense deposits
|
LM: membranoproliferative or endocapillary GN
IF: immune complexes in the basement membrane and mesangium
EM: subepithelial deposits
|
Clinical Presentation |
GN occurs after an infection-free latent period and is often asymptomatic.
May present with acute nephritis, ie, hematuria, edema, oliguria, etc |
Presents with acute nephritis and symptoms of concurrent Staphylococcus infection, ± rash; may worsen known comorbidities, eg, decompensated CHF |
Most commonly presents with AKI (oliguria, elevated creatinine, etc) with hematuria, rarely presents as acute nephritic syndrome |
Consider in any patient with a history of shunt surgery that presents with proliferative GN. Typically nonspecific symptoms, eg, fever, anemia |
Laboratory Findings |
|
|
|
± Hematuria, proteinuria, pyuria
± Positive ANCA, cryoglobulins
± Positive culture
|
Treatment |
Usually self-limited
If symptomatic, give supportive treatment with sodium/fluid restriction and diuretics. |
Eradicate the infection; then manage acute nephritis (see PSGN). Avoid steroids. |
Eradicate the infection with antibiotics and/or surgery; then manage the associated AKI. |
Immediate removal of infected shunt (source control) and aggressive antibiotic treatment to eradicate systemic infection |
Prognosis |
Typically self-resolved in pediatric patients. Less favorable outcomes for adult patients with comorbidities |
Quite variable, depending on severity of infection, patient characteristics, and antibiotic treatment |
Quite variable, depending on severity of infection, patient characteristics, and antibiotic treatment |
If identified and treated early, prognosis is often good. Possible delay in recognition may result in progressive kidney function impairment and end-stage kidney disease. |
AKI, acute kidney injury; ANCA, antineutrophil cytoplasmic antibodies; C3, complement factor 3; CHF, congestive heart failure; EM, electron microscopy; GN, glomerulonephritis; IE, infective endocarditis; IE-GN, infective endocarditis-associated glomerular nephropathy; IF, immunofluorescence; Ig, immunoglobulin; IVDU, intravenous drug use; LM, light microscopy; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; MSSA, methicillin-susceptible Staphylococcus aureus; PSGN, poststreptococcal glomerulonephritis; SAGN, Staphylococcus-associated glomerulonephritis; VA, ventriculoatrial; VP, ventriculoperitoneal. |